View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
July 26, 2021

Wyss Center and Artiria collaborate on cerebral vasospasm therapy

The technology developed by Artiria could aid in preventing brain arterial constriction after haemorrhagic strokes.

The Wyss Center and Artiria Medical have collaborated to expedite the development of a technology that can potentially lower mortality and enhance the quality of life in stroke patients.

The third major cause of disability globally, stroke can lead to bleeding in the brain.

This type of haemorrhagic stroke can cause an uncontrolled contraction of brain arteries called severe cerebral vasospasm, where entire brain regions become blood-deprived in the subsequent days, leading to severe consequences.

Developed by medical device company Artiria, the new technology can potentially aid in preventing arterial constriction after a haemorrhagic stroke.

Using a less-invasive electroactive endovascular probe, the technology interacts with some nerves from within the arteries in the lower brain for releasing arterial constriction in the entire brain.

The technology, which is based on the company’s endovascular platform, is centred around a biocompatible expandable system. This approach facilitates the safe delivery of electrical energy into the targeted arteries using flexible thin-film electrodes.

Wyss Center noted that the partners’ merged capabilities in electrode development will allow enhancement of the device’s ability to accurately control the treatment.

Artiria Medical CEO Guillaume Petit-Pierre said: “There is currently no truly effective solution that can treat cerebral vasospasm following haemorrhagic stroke, yet we know this is a leading cause of disability and death.

“We believe our technology has the potential to bring a new standard of care to patients and dramatically improve quality of life after stroke.”

The Swiss Innovation Agency, Innosuisse, extended support for the team to analyse and validate the therapy’s effectiveness in pre-clinical studies, in a bid to initiate trials in humans.

Wyss Center CEO Mary Tolikas said: “Collaborating with driven entrepreneurs like the Artiria team is key to our mission to translate neuroscience innovations into clinical solutions.”

At present, drugs or angioplasty to dilate the arteries with a balloon are the therapies available for cerebral vasospasm. These treatments have complications, such as the risk of further bleeding.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU